More than 20 biopharmaceutical companies around the world have pledged more than $1 billion toward the Antimicrobial Resistance (AMR) Action Fund that launched today.
Pledges include $100 million from Pfizer and $50 million from Boehringer Ingelheim.
An initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the fund’s goal is to bring two to four new antibiotics to market by 2030. The collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations is meant to re-invigorate antibiotic development — which has been lagging amid a rapid rise in antibiotic-resistant infections.
Get the full story on our sister site Drug Discovery & Development.